JP2014516970A - インターフェロン−αに対する抗体によって全身性エリテマトーデス、強皮症、および筋炎を治療する方法 - Google Patents

インターフェロン−αに対する抗体によって全身性エリテマトーデス、強皮症、および筋炎を治療する方法 Download PDF

Info

Publication number
JP2014516970A
JP2014516970A JP2014512069A JP2014512069A JP2014516970A JP 2014516970 A JP2014516970 A JP 2014516970A JP 2014512069 A JP2014512069 A JP 2014512069A JP 2014512069 A JP2014512069 A JP 2014512069A JP 2014516970 A JP2014516970 A JP 2014516970A
Authority
JP
Japan
Prior art keywords
day
average
days
max
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014512069A
Other languages
English (en)
Japanese (ja)
Inventor
ライアン・クリステ
ロリン・ロスコス
ウェンディ・ホワイト
ドミニク・エスジェン
ラジェシュ・ナーワル
ガブリエル・ロビー
Original Assignee
メディミューン，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディミューン，エルエルシー filed Critical メディミューン，エルエルシー
Publication of JP2014516970A publication Critical patent/JP2014516970A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2014512069A 2011-05-25 2012-05-23 インターフェロン−αに対する抗体によって全身性エリテマトーデス、強皮症、および筋炎を治療する方法 Pending JP2014516970A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161489949P 2011-05-25 2011-05-25
US61/489,949 2011-05-25
PCT/US2012/039098 WO2012162367A1 (en) 2011-05-25 2012-05-23 Methods of treating systemic lupus erythematosus, scleroderma, and myositis with an antibody against interferon-alpha

Publications (1)

Publication Number Publication Date
JP2014516970A true JP2014516970A (ja) 2014-07-17

Family

ID=47217695

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014512069A Pending JP2014516970A (ja) 2011-05-25 2012-05-23 インターフェロン−αに対する抗体によって全身性エリテマトーデス、強皮症、および筋炎を治療する方法

Country Status (9)

Country Link
EP (1) EP2714080A4 (pt)
JP (1) JP2014516970A (pt)
KR (1) KR20140043402A (pt)
CN (1) CN103732251A (pt)
BR (1) BR112013030242A2 (pt)
CA (1) CA2836926A1 (pt)
MX (1) MX2013013785A (pt)
RU (1) RU2013157177A (pt)
WO (1) WO2012162367A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9573996B2 (en) 2011-12-16 2017-02-21 Synthon Biopharmaceuticals B.V. Monoclonal antibodies to human proinflammatory cytokines and methods for treating inflammatory diseases
WO2013101771A2 (en) * 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
EP3008175B1 (en) * 2013-06-15 2019-08-07 Tocagen Inc. Immunosuppressive viral like particles based on gammaretrovirus
CN103740755A (zh) * 2013-12-23 2014-04-23 中国农业大学 猪ifit1基因在抗prrs病毒中的应用
RU2580301C1 (ru) * 2015-04-21 2016-04-10 Людмила Николаевна Хон Способ лечения системной красной волчанки человека
CN107058521B (zh) * 2017-03-17 2019-12-27 中国科学院北京基因组研究所 一种检测人体免疫状态的检测系统
WO2020074723A1 (en) * 2018-10-11 2020-04-16 Vivia Biotech Sl A method for determining the efficacy of treatment with a combination of drugs in a subject diagnosed with a disease and a method for classifying the utility of drug combinations in treatment of said subject
CA3117102A1 (en) * 2018-10-26 2020-04-30 Janssen Biotech, Inc. Type i interferon signatures and methods of use
JP2022527542A (ja) * 2019-04-04 2022-06-02 ヤンセン バイオテツク，インコーポレーテツド 抗ＩＦＮ－α／ω抗体の投与方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
SI2418220T1 (sl) * 2003-12-10 2017-10-30 E. R. Squibb & Sons, L.L.C. Interferon alfa protitelesa in njihova uporaba
KR20080025174A (ko) * 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
PT2219452E (pt) * 2007-11-05 2016-01-26 Medimmune Llc Métodos de tratamento de esclerodermia
KR101687032B1 (ko) * 2008-05-07 2016-12-15 아고스 쎄라퓨틱스, 인코포레이티드 인간 인터페론-알파에 대한 인간화 항체
WO2010042705A1 (en) * 2008-10-09 2010-04-15 Medimmune, Llc Antibody formulation
EP2701742A4 (en) * 2011-04-26 2015-03-18 Genentech Inc COMPOSITIONS AND METHOD FOR TREATING AUTOIMMUNE DISEASES

Also Published As

Publication number Publication date
RU2013157177A (ru) 2015-06-27
MX2013013785A (es) 2014-07-28
EP2714080A4 (en) 2014-11-19
CA2836926A1 (en) 2012-11-29
WO2012162367A1 (en) 2012-11-29
CN103732251A (zh) 2014-04-16
BR112013030242A2 (pt) 2016-12-06
EP2714080A1 (en) 2014-04-09
KR20140043402A (ko) 2014-04-09

Similar Documents

Publication Publication Date Title
JP2014516970A (ja) インターフェロン−αに対する抗体によって全身性エリテマトーデス、強皮症、および筋炎を治療する方法
JP6294585B2 (ja) 抗ｇｉｔｒ抗体
JP5926162B2 (ja) 炎症傷害の処置および評価
JP6938383B2 (ja) イヌインターロイキン４受容体アルファに対する抗体
KR20180064541A (ko) 항-il-2 항체 및 조성물 및 이의 용도
KR102527840B1 (ko) 인터페론 베타 항체 및 그의 용도
KR102320059B1 (ko) 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획
KR20140048877A (ko) 자가면역 질환의 치료를 위한 조성물 및 방법
MX2013011130A (es) Metodos de administracion de antagonistas de integrina beta7.
CA3200884A1 (en) Steroid sparing
EP4229081A1 (en) Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
US20220396630A1 (en) Type i interferon inhibition in systemic lupus erythematosus
US20200317771A1 (en) Method of Administration of an Anti-IFN-alpha/-omega Antibody
JP2023113655A (ja) 小児の障害を処置する方法
JP7202893B2 (ja) 炎症性腸疾患を治療する方法
WO2008140455A1 (en) Treatment of radiation and chemo-therapy induced fibrosis using novel anti-il 13 monoclonal antibodies
TWI826839B (zh) CD1a抗體及其用途
US20110104153A1 (en) Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients
AU2012258819A1 (en) Methods of treating systemic lupus erythematosus, scleroderma, and myositis with an antibody against interferon-alpha
CN114555120A (zh) 用抗il12/il23抗体治疗溃疡性结肠炎的安全且有效的方法
TW202304981A (zh) 抗ｉｌ－２７抗體及其用途